Entrada Therapeutics Inc Net Assets
Entrada Therapeutics Inc net assets. Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) has net assets worth $233.41 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($298.88 Million) and total liabilities ($65.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Entrada Therapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $233.41 Million |
| % of Total Assets | 78.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | 2.48% |
| 10-Year Change | N/A |
| Growth Volatility | 43.23 |
Net Assets of Entrada Therapeutics Inc (2019–2025)
Net assets of Entrada Therapeutics Inc from 2019 to 2025. This chart illustrates how Entrada Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Entrada Therapeutics Inc to measure how much of total assets are equity-financed.
Annual Net Assets for Entrada Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Entrada Therapeutics Inc from 2019 to 2025. For live market cap and overall valuation, see Entrada Therapeutics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $306.13 Million | -28.59% |
| 2024-12-31 | $428.68 Million | +76.88% |
| 2023-12-31 | $242.36 Million | +14.02% |
| 2022-12-31 | $212.55 Million | -28.84% |
| 2021-12-31 | $298.72 Million | +819.98% |
| 2020-12-31 | $-41.49 Million | -167.37% |
| 2019-12-31 | $-15.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Entrada Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25710600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Entrada Therapeutics Inc Net Assets Breakdown (December 2025)
Entrada Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $652.00K | 0.21% |
| Other Components | $578.57 Million | 188.99% |
| Total Equity | $306.13 Million | 100.00% |
Entrada Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Entrada Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Arkora Hydro Tbk
JK:ARKO
|
$190.47 Million |
|
TechTarget, Inc. Common Stock
NASDAQ:TTGT
|
$190.50 Million |
|
ProQR Therapeutics BV
NASDAQ:PRQR
|
$190.51 Million |
|
Spurcorp
JSE:SUR
|
$190.53 Million |
|
QuantaSing Group Limited American Depositary Shares
NASDAQ:QSG
|
$190.34 Million |
|
Amcil Ltd
AU:AMH
|
$190.28 Million |
|
Dream Office Real Estate Investment Trust
TO:D-UN
|
$190.12 Million |
|
GTM Holdings Corp
TW:1437
|
$190.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Entrada Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 428,678,000 to 306,133,000, a change of -122,545,000 (-28.6%).
- Net loss of 143,750,000 reduced equity.
- Share repurchases of 462,000 reduced equity.
- Other comprehensive income increased equity by 695,000.
- Other factors increased equity by 20,972,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-143.75 Million | -46.96% |
| Share Repurchases | $462.00K | -0.15% |
| Other Comprehensive Income | $695.00K | +0.23% |
| Other Changes | $20.97 Million | +6.85% |
| Total Change | $- | -28.59% |
Book Value vs Market Value Analysis
This analysis compares Entrada Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.66x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-14.81 | $4.89 | x |
| 2020-12-31 | $-1.33 | $4.89 | x |
| 2021-12-31 | $9.57 | $4.89 | x |
| 2022-12-31 | $6.79 | $4.89 | x |
| 2023-12-31 | $7.33 | $4.89 | x |
| 2024-12-31 | $10.99 | $4.89 | x |
| 2025-12-31 | $7.40 | $4.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Entrada Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -565.48%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.23x
- Recent ROE (-46.96%) is below the historical average (-13.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.10 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.37 Million |
| 2021 | -16.76% | 0.00% | 0.00x | 1.02x | $-79.94 Million |
| 2022 | -41.15% | -346.23% | 0.10x | 1.19x | $-108.71 Million |
| 2023 | -2.76% | -5.18% | 0.27x | 1.94x | $-30.92 Million |
| 2024 | 15.31% | 31.13% | 0.40x | 1.23x | $22.76 Million |
| 2025 | -46.96% | -565.48% | 0.07x | 1.23x | $-174.36 Million |
Industry Comparison
This section compares Entrada Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $150,779,214
- Average return on equity (ROE) among peers: -66.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Entrada Therapeutics Inc (TRDA) | $233.41 Million | 0.00% | 0.28x | $190.40 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $25.47 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $14.83 Million | -365.49% | 3.32x | $238.46 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $16.14 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $724.08 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $25.82 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $7.48 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potent… Read more